A 2-Part Trial: a Randomized 6-day Repeat-dose, Parallel-group Study in Subjects With T2DM to Assess the Safety and Tolerability of GSK1614235 Compared to Placebo and Sitagliptin; and a Randomized Single-dose, Food Effect Study in Healthy Volunteers to Assess Safety and Tolerability of GSK1614235
Phase of Trial: Phase I
Latest Information Update: 12 Jun 2017
At a glance
- Drugs GSK 1614235 (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 13 May 2011 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 13 May 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 May 2010 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.